Jefferies Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $60
Jefferies analyst Michael Yee initiates coverage on Adagio Therapeutics (NASDAQ:ADGI) with a Buy rating and announces Price Target of $60.
Stifel Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $57
Stifel analyst Stephen Willey initiates coverage on Adagio Therapeutics (NASDAQ:ADGI) with a Buy rating and announces Price Target of $57.
Guggenheim Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $40
Guggenheim analyst Seamus Fernandez initiates coverage on Adagio Therapeutics (NASDAQ:ADGI) with a Buy rating and announces Price Target of $40.
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck’s Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc.
78 Biggest Movers From Friday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
66 Biggest Movers From Yesterday
Gainers
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share.
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)